@article{Garcia_Mesquita_Rosales_Moura_Araujo_Leitão_Barroso_Gurgel_Filho_Duarte_Duarte_Duarte_Lemes_Duarte_2020, title={Myelodysplastic Syndrome / Secondary Acute Myeloid Leukemia: role of the allogeneic hematopoietic stem cell transplantation}, volume={1}, url={https://www.jbmtct.com.br/seer/index.php/jbmtct/article/view/9}, DOI={10.46765/2675-374X.2020v1n1p15-18}, abstractNote={<p>Secondary Acute Myeloid Leukemia (s-AML) refers to the development of leukemia after cytotoxic therapy, immunosuppressive therapy, radiation or an antecedent hematological disorder, such as Myelodysplastic Syndrome (MDS). A s-AML corresponds to 10% to 30% of AML cases and is defined by the presence of at least 20% of blast cells, representing a category of disease with a poor prognosis. Allogeneic hematopoietic stem cell transplan­tation (Allo-HSCT) is the only option with curative potential for patients with s-AML, but recurrence after HSCT emerges as a frequent cause of treatment failure and course with high mortality. We report the case of a patient with s-AML after MDS, who underwent HSCT due to refractoriness to other treatments, recovering the bone marrow with dysplasia, be­ing classified as AREB1.</p>}, number={2}, journal={JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY}, author={Garcia, Yhasmine Delles Oliveira and Mesquita, Juliene Lima and Rosales, Yensy Mariana Zelaya and Moura, Anna Thawanny Gadelha and Araujo, Beatriz Stela Gomes de Sousa Pitombeira and Leitão, João Paulo de Vasconcelos and Barroso, Karine Sampaio Nunes and Gurgel, Lívia Andrade and Filho, Francisco Dario Rocha and Duarte, João Vitor Araújo and Duarte, Isabella Araújo and Duarte, Beatrice Araújo and Lemes, Romélia Pinheiro Gonçalves and Duarte, Fernando Barroso}, year={2020}, month={Jul.}, pages={15–18} }